Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Top Cited Papers
- 15 April 2010
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 375 (9724), 1437-1446
- https://doi.org/10.1016/s0140-6736(10)60172-9
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 StudyJournal of Clinical Oncology, 2009
- Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy ResistanceThe American Journal of Pathology, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.Journal of Clinical Oncology, 1997
- The Antiandrogen Withdrawal Syndrome in Relapsed Prostate CancerEuropean Urology, 1997